About Me
Wontak’s /one-tɒk; 원탁/ professional goal is to help improve cancer patient care. He is obsessed with understanding neoplasia and leveraging that understanding to develop therapeutics for patients. Wontak has a broad background in biophysics with specific training in small molecule drug discovery and preclinical cancer models. Notably, Wontak studied the mechanism of alvocidib, a CDK9 inhibitor, in acute myeloid leukemia. His discovery has led to ongoing industry- sponsored clinical trials. Wontak comes to the Huntsman Cancer Institute to study oncogenes' influence on tumorigenesis, develop disease models that inform clinical decisions, and discover novel drug targets and design new regimens for cancer patient care.